Hong Van Tieu, MD, MS
Head, Laboratory of Infectious Disease Prevention
Associate Member, Lindsley F. Kimball Research Institute
Phone: +1 (212) 570-3081
Established in 1993 and previously led by Dr. Beryl Koblin, the Laboratory of Infectious Disease Prevention is a leader in HIV and infectious disease epidemiology and prevention research. We are part of the largest clinical trials program devoted to the development and testing of preventive HIV vaccines worldwide (www.hvtn.org). As part of the global response to COVID-19 caused by SARS-CoV-2 virus, we are also part of the clinical trials program devoted to the development and testing of SARS-CoV-2 vaccines and monoclonal antibodies to prevent COVID-19. We use epidemiology to stay up to date on who is at risk for HIV and other infectious diseases and why. We design and test innovative prevention strategies to increase HIV testing and pre-exposure prophylaxis (PrEP) uptake and reduce risk. We conduct our epidemiology and clinical studies and community engagement through our research site, Project ACHIEVE (www.projectachieve.org).
Our research collaborators include Columbia University, Harlem Prevention Center, and Bronx Prevention Center. Together, we form the NIH-funded Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit.
SARS-CoV-2 Vaccine and Monoclonal Antibody Studies
In collaboration with the NIH/NIAID-funded COVID-19 Prevention Trials Network (CoVPN) and with the Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit, our research involves implementation of multiple Phase 1-3 SARS-CoV-2 clinical research trials to test the safety, tolerability, and efficacy of vaccine products and monoclonal antibodies to prevent COVID-19.
HIV Vaccine and Monoclonal Antibody Studies
In collaboration with the NIH/NIAID-funded HIV Vaccine Trials Network (HVTN) and with the Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit, our research involves implementation of multiple Phase 1-3 clinical research trials to test the safety, tolerability, and efficacy of HIV vaccine products and monoclonal antibodies to prevent HIV infection.
HIV Injectable Pre-Exposure Prophylaxis Study
In collaboration with the NIH/NIAID-funded HIV Prevention Trials Network (HPTN), this multi-site, multi-country HPTN 083 study is a Phase 2b/3 study comparing injectable cabotegravir to emtricitabine/tenofovir (FTC/TDF) for preventing HIV infection in men who have sex with men and transgender women.
Neighborhoods, Networks, and the HIV Care Continuum
This NIH/NIMH-funded three-phase research study involves a mixed methods approach to ascertain unique, salient neighborhood and network factors that influence HIV care continuum outcomes (retention in care, ART adherence, and viral suppression) among HIV-infected men who have sex with men in New York City using qualitative interviews and spatial analysis and multilevel modeling. This is followed by a longitudinal study among 500 HIV-infected MSM over two years to evaluate the influence of neighborhoods and networks on HIV care continuum over time.
Pre-Exposure Prophylaxis in Women
This NIH/NIMH-funded R34-funded three-phase project seeks to develop and pilot an intervention to enhance uptake of pre-exposure prophylaxis (PrEP) among women at risk for HIV, and support adherence, and linkage to care in New York City and Philadelphia. Text based messaging will be used to encourage PrEP adherence, and the feasibility and acceptability of the intervention will be tested.
Hepatitis C Infections among Men Who Have Sex with Men
This Merck Investigator Sponsored Program (MISP)-funded research aims to determine the prevalence of recent and chronic hepatitis C (HCV) infections among MSM in NYC, map HCV infections by home, social, and sexual neighborhoods, and determine clusters of genetically linked HCV variants among recently and chronically HCV-infected MSM in NYC using phylogenetic analysis.
Barriers and Facilitators to Blood Donation
This pilot study seeks to identify and describe motivations, barriers, and facilitators to blood donation among Black donors by analyzing YouTube video content and qualitative data analysis.
- NIH/NIMH R21 MH124474-01 (Tieu/Frye), 07/2020 - 06/2022, Mixed Methods Study Evaluating Violence and HIV Care and Viral Suppression
- NIH R01 MH118960 (Tieu), 05/2019 – 02/2023 Neighborhoods, Networks, and the HIV Care Continuum among HIV-infected MSM in NYC
- NIH UM1AI068614-14S1 (Corey, subcontract to Tieu), 08/01/2020 – 02/28/2022, COVID-19 Prevention Trials Network for Phase 3 COVID-19 Vaccine and Monoclonal Antibody Trials
- 2UM1A069470 (Hammer/El-Sadr, subcontract to Tieu), 12/1/2013 - 11/30/2027, Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit
- UM1 AI068619 (Cohen, subcontract to Tieu), 1/1/2017 – 12/31/2021, HIV Prevention Trials Network (HPTN) 083
- Gilead NoCo Grant (Tieu), 07/2019 - 06/2022, Prevalence of Hepatitis C and B Infections and Hepatitis C Phylogenetics among Men Who Have Sex with Men and Transwomen in the U.S.
- Margarita Ashkinazi, Research Assistant
- Breanne Baez, Research Counselor
- Christina Barron, Research Recruitment Specialist
- Abena Bosompem, Research Counselor
- Eddie Bravo, Recruitment Specialist
- Bart Buurman, Research Counselor
- Arialdy Chavez, Research Recruitment Specialist
- Joie Cooper, Research Counselor
- Nikki Englert, Senior Research Counselor
- Gabrielle Figueroa, Research Assistant
- Chantel Fletcher, Research Counselor
- Victoria Frye, DrPH, MPH, Associate Member
- Lauren Guerra, Research Assistant
- Joseph Kim, Research Assistant
- Tiffany Kim, Research Clinician
- Stephanie Kung, Project Manager of Clinical Studies
- Steven Lam, Research Counselor
- Jeffrey Li, Research Assistant
- Jay Loeffel, Senior Administrator
- Pablo Lundie, Coordinator
- Elsie Marius, Research Counselor
- Sauda Muhammad, Manager of Clinical Studies
- Inja Noh, Research Nurse
- Leila Noori, Lab Coordinator
- Geneva Ortiz, Senior Research Counselor
- Lillian Pao, Research Counselor
- Nadine Pratt, Research Assistant
- Alaa Salem, Research Recruitment Specialist
- Maria Veronica Sanchez, Research Nurse
- Ruth Santos, Research Nurse
- Mahtab Sheikh, Data Management Specialist
- Kipa Sherpa, Research Assistant
- Jorge Soler, PhD, MPH, Assistant Member
- Ilyas Tezekbaev, Research Assistant
- Tanisha Thakurdeen, Lab Coordinator
- DaShawn Usher, Community Engagement
- Jonathan Washington, Administrator
- Jenny Yee-Levin, Research Clinician
Education and Training
MD, Mount Sinai School of Medicine
MS, Epidemiology, Columbia University Mailman School of Public Health
Internal medicine residency, Department of Medicine, Boston University Medical Center
Infectious diseases fellowship, Division of Infectious Diseases/Department of Medicine, Columbia University Medical Center
Infectious disease epidemiology research fellowship, Center for Infectious Disease Epidemiologic Research, Columbia University Mailman School of Public Health
Teitelman AM, Koblin BA, Brawner BM, Davis A, Darlington C, Lipsky RK, Iwu E, Bond KT, Westover J, Fiore D, Tieu HV. Just4Us: Development of a Counselor-Navigator and Text Message Intervention to Promote PrEP Uptake Among Cisgender Women at Elevated Risk for HIV. J Assoc Nurses AIDS Care 2021. doi: 10.1097/JNC.0000000000000233. [Epub ahead of print]
Teitelman AM, Chittamuru D, Koblin BA, Davis A, Brawner BM, Fiore D, Broomes T, Ortiz G, Lucy D, Tieu HV. Beliefs Associated with Intention to Use PrEP Among Cisgender U.S. Women at Elevated HIV Risk. Arch Sex Behav 2020;49(6):2213-2221. doi:10.1007/s10508-020-01681-3.
Kallas EG, Grunenberg NA, Yu C, Manso B, Pantaleo G, Casapia M, Baden LR, Valencia J, Sobieszczyk M, Tieu HV, Allen M, Hural J, Graham BS, Kublin J, Gilbert PB, Corey L, Goepfert PA, McElrath MJ, Johnson RP, Huang Y, Frahm N. Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. Sci Transl Med 2019;11(519). pii: eaaw1673. doi: 10.1126/scitranslmed.aaw1673.
Rouphael NG, Morgan C, Li SS, Jensen R, Sanchez B, Karuna S, Swann E, Sobieszczyk ME, Frank I, Wilson GJ, Tieu HV, Maenza J, Norwood A, Kobie J, Sinangil F, Pantaleo G, Ding S, McElrath MJ, De Rosa SC, Montefiori DC, Ferrari G, Tomaras GD, Keefer MC; HVTN 105 Protocol Team and the NIAID HIV Vaccine Trials Network. DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. J Clin Invest 2019;129(11):4769-4785. doi: 10.1172/JCI128699.
Scott H, Vittinghoff E, Irvin R, Liu A, Nelson L, Del Rio C, Magnus M, Mannheimer S, Fields S, Tieu HV, Kuo I, Shoptaw S, Grinsztejn B, Sanchez J, Wakefield S, Fuchs JD, Wheeler D, Mayer KH, Koblin BA, Buchbinder S. Development and Validation of the Personalized Sexual Health Promotion (SexPro) HIV Risk Prediction Model for Men Who Have Sex with Men in the United States. AIDS Behav 2020;24(1):274-283. doi: 10.1007/s10461-019-02616-3.
Hermanstyne KA, Green HD Jr, Tieu HV, Hucks-Ortiz C, Wilton L, Shoptaw S. The Association Between Condomless Anal Sex and Social Support Among Black Men Who Have Sex With Men (MSM) in Six U.S. Cities: A Study Using Data from the HIV Prevention Trials Network BROTHERS Study (HPTN 061). AIDS Behav 2018; doi: 10.1007/s10461-018-2315-y.
Elizaga ML, Li SS, Kochar NK, Wilson GJ, Allen MA, Tieu HV, Frank I, Sobieszczyk ME, Cohen KW, Sanchez B, Latham TE, Clarke DK, Egan MA, Eldridge JH, Hannaman D, Xu R, Ota-Setlik A, McElrath MJ, Hay CM; NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team. Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial. PLoS One 2018;13(9):e0202753. doi: 10.1371/journal.pone.0202753. eCollection 2018.
Tieu HV, Laeyendecker O, Nandi V, Rose R, Fernandez R, Lynch B, Hoover DR, Frye V, Koblin BA Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City. PLoS One 2018;18;13(7):e0200269. doi: 10.1371/journal.pone.0200269. eCollection 2018.
Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Tieu HV, Tomaras GD, Deal A, Goodman D, Bailer RT, Ferrari G, Jensen R, Hural J, Graham BS, Mascola JR, Corey L, Montefiori DC2; HVTN 104 Protocol Team; and the NIAID HIV Vaccine Trials Network. PLoS Med 2017;14(11):e1002435. doi:10.1371/journal.pmed.1002435.
Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network. DNA priming increases frequency of T-cell responses to a VSV HIV vaccine with specific enhancement of CD8+ T-cell responses by IL-12 pDNA. Clin Vaccine Immunol 2017. pii: CVI.00263-17. doi: 10.1128/CVI.00263-17.
Markowitz M, Frank I, Grant RM, Mayer KM, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Tieu HV, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart, AR, Smith KY. Spreen W. ECLAIR: a randomised phase IIa safety and pharmacokinetic study of cabotegravir long-1 acting injection 800 mg every 12 weeks in HIV-uninfected men. Lancet Infectious Diseases 2017;4(8):e331-e340. doi: 10.1016/S2352-3018(17)30068-1.
Frye V, Nandi V, Egan JE, Cerda M, Rundle A, Quinn JW, Sheehan D, Ompad DC, Tieu HV, Greene E, Koblin B. Associations Among Neighborhood Characteristics and Sexual Risk Behavior Among Black and White MSM Living in a Major Urban Area. AIDS Behav 2016; 21(3):870-890. doi: 10.1007/s10461-016-1596-2.
Tieu HV, Nandi V, Hoover DR, Lucy D, Stewart K, Frye V, Cerda M, Ompad D, Latkin C, Koblin BA on behalf of the NYC M2M Study Team. Do Sexual Networks of Men Who Have Sex with Men in New York City Differ by Race/Ethnicity? AIDS Patient Care and STDs 2016: 30(1):39-47. doi:10.1089/apc.2015.0237.
Tieu HV, Liu TY, Hussen S, Connor M, Wang L, Buchbinder S, Wilton L, Gorbach P, Mayer K, Griffith S, Kelly C, Elharrar V, Phillips G, Cummings V, Koblin B, Latkin C; HPTN 061. Sexual Networks and HIV Risk among Black Men Who Have Sex with Men in 6 U.S. Cities. PLoS ONE 2015: 10(8):e0134085. doi: 10.1371/journal.pone.0134085.
Tieu HV, Nandi V, Frye V, Stewart K, Oquendo H, Bush B, Cerda M, Hoover DR, Ompad D, Koblin BA. Concurrent Partnerships and HIV Risk among Men Who Have Sex with Men in New York City. Sexually Transmitted Diseases 2014:41(3):200-8.
Tieu HV, Rolland M, Hammer S, Sobieszczyk ME. Translational Research Insights from Completed HIV Vaccine Efficacy Trials. JAIDS 2013:63 Suppl 2:S150-4.
Tieu HV, Li X, Donnell D, Vittinghoff E, Buchbinder S, Parente ZG, Koblin BA. Anal Sex Role Segregation and Versatility among Men Who Have Sex with Men: EXPLORE Study. JAIDS 2013;64(1):121-125.
Edwards-Jackson N, Phanuphak N, Tieu HV, Chomchey N, Teeratakulpisarn N, Sathienthammawit W, Pakam C, Pharachetsakul N, Sobieszczyk ME, Phanuphak P, Ananworanich J. HIV Serostatus Disclosure is Not Associated with Safer Sexual Behavior among HIV-positive Men Who Have Sex with Men and Their Partners at Risk for Infection in Bangkok, Thailand. AIDS Research and Therapy 2012;9(1):38.
Tieu HV, Spikes P, Patterson J, Bonner S, Egan JE, Goodman K, Stewart K, Frye V, Xu G, Hoover DR, Koblin BA. Sociodemographic and Risk Behavior Characteristics Associated with Unprotected Sex with Women among Black Men Who Have Sex with Men and Women in New York City. AIDS Care 2012;24(9):1111-9.
Tieu HV, Xu G, Bonner S, Spikes P, Egan JE, Goodman K, Stewart K, Koblin BA. Sexual Partner Characteristics, Serodiscordant/Serostatus Unknown Unprotected Anal Intercourse and Disclosure among HIV-infected and Uninfected Black Men Who Have Sex with Men in New York City. Sexually Transmitted Diseases 2011;38(6):548-54.
Tieu HV, Murrill C, Xu G, Koblin BA. Sexual Partnering and HIV Risk among Black Men Who Have Sex With Men: New York City. Journal of Urban Health 2010;87:113-21.
Teitelman AM, Koblin BA, Brawner BM, Davis A, Darlington C, Lipsky RK, Iwu E, Bond KT, Westover J, Fiore D, Tieu HV.